Table 2.
Progression-free and overall survival in regard of dosimetry in glioblastoma patients with conventional fractionated radiotherapy
| Cofactors | Number of patients, ≥40 Gy/<40 Gy | Median PFS, ≥40 Gy |
Median PFS, <40 Gy |
p value | Median OS, ≥40 Gy |
Median OS, <40 Gy |
p value |
|---|---|---|---|---|---|---|---|
| Mean IL ventricle dose | 30/24 | 9.0 (6.3–11.7) | 5.1 (3.5–6.8) | 0.11 | 21.6 (18.5–24.7) | 18. (11.2–24.8) | 0.15 |
| Mean CL ventricle dose | 7/47 | 10.1 (4.1–16.1) | 7.2 (5.0–9.4) | 0.26 | 21.6 (12.6–30.6) | 21.2 (16.0–26.5) | 0.65 |
| Mean IL SVZ dose | 31/23 | 8.5 (6.3–10.2) | 5.2 (3.1–7.3) | 0.01 | 21.3 (17.5–25.2) | 18.0 (11.4–24.6) | 0.19 |
| Mean CL SVZ dose (≥30 Gy versus <30 Gy) |
12/42 | 10.1 (8.9–11.3) | 6.8 (4.8–9.0) | 0.03 | 21.6 (12.2–31.0) | 21.2 (16.4–26.1) | 0.29 |
| Mean IL DG dose | 22/32 | 7.3 (5.4–9.2) | 7.8 (5.0–10.5) | 0.22 | 20.8 (12.5–29.1) | 21.3 (15.6–27.1) | 0.49 |
| Mean CL DG dose (≥30 Gy versus <30 Gy) |
4/50 | 9.4 (0.28–18.6) | 7.3 (6.3–8.3) | 0.84 | 15.4 (−5.96–36.8) | 21.3 (16.7–25.8) | 0.85 |
CI: confidence interval; HR: hazard ratio; PFS: progression-free survival; OS: overall survival; IL: ipsilateral; CL: contralateral; SVZ: subventricular zone; Gy: gray.